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multidisciplinary team, the FDA will present the applica-
tion to a committee of nongovernment experts, in the
case of vascular prostheses, the Circulatory System
Advisory Panel, for a recommendation about market
approval. The Advisory Panel reviews the application in a
public forum with opportunity provided for relevant
input from any interested parties.2
This procedure was followed to gain approval of PMA
applications submitted by Medtronic AVE for their
AneuRx device, and by Guidant Corporation for the
Ancure system. Clinical trials for these PMA applications
began as early as 1994. Inclusion criteria for the pivotal
clinical trials limited treatment to nonemergency cases
meeting indications for surgical aneurysmectomy.
Nonrandomized controls underwent open surgical treat-
ment. In the Ancure study, controls included patients in
whom aneurysm anatomy precluded endovascular grafting
(eg, inadequate aortic anchoring sites). In the Ancure
study 268 patients were enrolled who were receiving
bifurcated grafts and 153 who were treated with tube
grafts at 22 medical centers. A concurrent control cohort
of 111 patients underwent conventional surgery. The
AneuRx study was conducted at 13 clinical centers where
66 surgical controls were enrolled as a modified concur-
rent control group before the recruitment of 416 patients
into the pivotal study with a bifurcated endovascular aor-
tic graft only for the experimental arm was initiated. These
less robust nonrandomized control study designs were
necessary because of the difficulty encountered in recruit-
ing patients to a randomized study once the endovascular
option became available. Patients were followed up for at
least 1 year for adverse events, clinical utility, and patient
acceptance measured with quality of life evaluations.
Effectiveness was assessed as procedural success in deploy-
ment, success with exclusion of aneurysm from the circu-
lation, and absence of AAA rupture. Change in aneurysm
size was also captured. Follow-up of treatment arms
included regular imaging reviewed by independent core
laboratories. The outcome of these studies is published in
“Summaries of Safety and Effectiveness” (SS&E) and is
The Food and Drug Administration (FDA) approved
the marketing of two endovascular prosthetic graft devices
for the treatment of infrarenal abdominal aortic aneurysm
(AAA) in September 1999. Endovascular vessel grafting is
perhaps the most important change in vascular surgical
practice to have taken place in the five decades since the
introduction of AAA resection. This has also stimulated
investigations into a variety of percutaneous and endo-
vascular treatment approaches for vascular pathologic 
conditions. Since becoming commercially available,
approximately 20,000 of these devices have been im-
planted worldwide and have been the subject of numerous
academic reports highlighting both the clinical benefits
and concerns for complications associated with an impor-
tant but as yet evolving technology.1 This editorial pro-
vides an FDA perspective on the performance of the
device since its approval and how this must influence
future use of the endovascular graft.
For approval of the marketing of implanted medical
devices that present significant risk to patients in the
event of failure, as endovascular grafts do, the FDA
requires establishment of both safety and effectiveness
when used as labeled. Evidence of this is obtained from a
variety of sources that may include in vivo and in vitro
experiments and, most important, clinical trials. A clini-
cal study in which a significant risk device is used must be
undertaken with protocols approved by the FDA in an
application for an investigational device exemption
(IDE). The sponsor of a new device submits a premarket
approval (PMA) application to the FDA that includes
data from the IDE studies. After an in-house review by a
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included in the device labeling.3,4 The clinical data, sup-
ported with both in vivo and in vitro experiments, indi-
cated a clinical utility for the device on the basis of reduced
morbidity and improved quality of life and acceptable
safety and effectiveness variables. A mortality benefit com-
pared with open surgery was not demonstrated despite the
lesser invasiveness of this endovascular procedure.
Concern for an early disturbing incidence of perigraft flow
(endoleak) was assuaged by the elimination of communi-
cation of the AAA sac with the circulation in the course of
patient follow-up.
The PMA application process provides a snapshot of
device performance in a highly controlled clinical environ-
ment. The limited 1-year follow-up was considered
acceptable for outcomes of a study with patients exhibit-
ing considerable comorbidity. The Advisory Panel, in rec-
ommending market approval, addressed the duration of
follow-up with a requirement that all study patients con-
tinue to be followed up for 5 years. The FDA found in an
assessment of risk versus benefit and the related clinical
utility that the data supported device approval and con-
curred with the Advisory Panel recommendation. The
FDA did not stipulate criteria for patient selection, which
was deemed a practice of medicine issue by the Advisory
Panel.5 The FDA does, however, publish the data related
to the PMA approval process in the “Summaries of Safety
and Effectiveness” and the device labeling, and these are
accessible to clinicians for decisions about patient selection
and other clinical issues.
The real world practice of vascular surgery differs con-
siderably from that of a clinical study that adheres to a
rigid protocol and is undertaken at well-recognized clini-
cal centers. The FDA monitors device performance in this
open market environment. In doing so it depends to a
large degree on passive reporting in the clinical literature
and at professional conferences, annual reports that man-
ufacturers are required to submit on PMA device status to
the Agency, and the mandatory medical device reporting
by sponsors to the FDA concerning device-related adverse
events. The FDA is, however, in the unique position of
having recourse to the raw data available from a required
postmarket study undertaken with an approved protocol.
The FDA can respond to failures in a device’s structural
integrity and function with regulatory interventions at the
manufacturing level ranging from rescission of market
approval to requiring mailing of informational “Dear
Doctor” letters. On the other hand, the Agency has lim-
ited instruments available with which to influence clinical
practice. The clinical milieu reacts largely to peer-review
influences. The FDA does accept a responsibility to dis-
seminate any information surfacing during marketing that
is either a supplement to or a correction of that contained
in its published summary of safety and effectiveness and
the labeling.
The treatment of AAA with endovascular grafts is in
an early phase of both the technologic development and
determination of the appropriate arena of clinical applica-
bility. In fact, the FDA has reviewed more than 36 IDE
applications for endovascular aortic devices. The two
devices approved for marketing are quite dissimilar in their
structural characteristics. The Ancure system has active fix-
ation of the graft with hooks and a flexible, unsupported
graft prosthesis. The AneuRx has the graft supported by
stents in its entire length and relies on radial force applied
to the aortic wall by self-expanding stents for fixation. The
AneuRx device has a modular construction where one iliac
limb is separately introduced into the aortic trunk to cre-
ate the bifurcated aortoiliac configuration. The Ancure
system is preconstructed as either a bifurcated or tubular
device. Both devices underwent design changes in the
course of the IDE study. In many instances, improvements
were made to address procedural failure. Bailout surgical
repair of injury occurring during endovascular procedure
or abandonment with conversion to open aneurysmec-
tomy has been recently reported as necessary in 2% to 7%
of cases.6,7
The importance of accurately establishing the
anatomy and the degenerative pathology of the AAA
and related aorta and iliac arteries to ensure procedural
success, stable anchoring of the graft, and satisfactory
long-term outcome is critical. The conventional imaging
of aneurysmal disease, which relies on ultrasound and
aortography, is generally inadequate for the endovascu-
lar procedure. Contrast-enhanced computerized tomog-
raphy, often supplemented with three-dimensional
reconstruction, is increasingly viewed as necessary for
appropriate patient preoperative selection and postpro-
cedural follow-up.8
Continuing experience has confirmed that the antici-
pated significant improvement in perioperative morbidity
is achieved with the reduction of hospital stay to 4 or 5
days after endovascular-treated AAA, compared with an
average hospitalization of 10 days after surgical aneurysm-
ectomy.8 The perioperative mortality rate for the endovas-
cular procedure has been reported comparable to that for
open surgery. The mortality rate in one study was found
to be 1.5% for patients in ASA Class 1 and 12% for those
in Class 4, conceptually those most likely to have benefited
from this less-invasive procedure.6
The primary objective in treating AAA is to obviate risk
of catastrophic rupture. This is almost invariably accom-
plished with open surgical treatment; a 0.44% rate of false
aneurysm rupture was reported in a 6-year follow-up of
one series.9 Delayed rupture, however, after endovascular
treatment has been reported in a registry of 2464 patients
with a cumulative rate at 1 year of approximately 1%6 and
of 2% in 1046 patients in an IDE study followed for 3
years.10 These figures are probably conservative because
only patients positively identified with ruptures are com-
puted, excluding patients with an unidentified cause of
death. The mortality rate of emergency conversion surgery
for rupture in both reports was similar to that for de novo
aneurysm rupture at 40% to 50%.
Imaging may identify signs that presage occurrence
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of delayed rupture after endovascular treatment of AAA.
While some of the premonitory signs have been linked to
the pathogenesis of delayed rupture, others remain con-
jectural. Factors incriminated include persistent perigraft
flow, particularly of Type 1; migration of attachment
cuffs, possibly associated with ongoing aortic cuff dilata-
tion; loss of integrity of graft prosthesis due to stent frac-
tures, suture breaks, or fabric tears; extreme graft
kinking; and separation of modular components, possibly
due to aneurysm remodeling. Aneurysm enlargement,
with or without endoleak, is an extremely sensitive indi-
cator for risk of impending aneurysm rupture. Failure of
an aneurysm to diminish in size and the effect of trans-
mitted systolic pulsatile pressure to the aneurysm wall,
termed endopressure, are perceived as more controversial
causes for delayed rupture. The risk for delayed rupture
is sufficiently substantial to justify the need for moni tor-
ing AAA patients treated with endovascular grafts indef-
initely for signs of treatment failure. Repetitive contrast-
enhanced computerized tomography and color flow
Doppler interrogation for endoleak are believed neces-
sary, supplanting standard abdominal radiologic and
sonographic imaging. Endovascularly treated aneurysm
has required conversion to open aneurysmectomy at a
rate of 1% of cases during the first year in one reported
study, increasing to 3.7% by the second year after implant.
Conversion, far from being a benign procedure, carried a
mortality risk approximating 25% irrespective of the rea-
son for the graft failure.6
Apart from the conversion of endovascularly treated
AAA to surgical resection, adjunctive interventions have
been required to ensure aneurysm exclusion in 10% to
20% of cases. The types of adjunctive procedures used
include stent-graft extensions for inadequate proximal or
distal fixation sites or to correct separated modular attach-
ments, endovascular occlusion of collateral sources of
endoleak, and the stenting of the graft to correct obstruc-
tive twisting during deployment.
The importance of endovascular treatment of AAA
should not be diminished by the demonstration of mid-
and long-term problems occurring with first generation
devices. Modifications to devices have been or are being
made, under a regulatory controlled process, to specifi-
cally address the observations mentioned. Continuing
clinical experience is defining the niche population appro-
priate for treatment with this modality, while the diag-
nostic tools to more accurately identify this patient cohort
are being developed. The FDA undertakes an evaluation
of risk versus benefit before issuing marketing approval
for a device based on a global health care perspective.
Whether a device meets the requirements for an individ-
ual patient is determined by a mélange of variables that
include both the patient’s vascular pathologic condition
and systemic health and an educated estimate by the
physician of the risks and benefits that this new therapy
provides the patient compared with alternative treat-
ments. The siren call of short-term advantage of endovas-
cular treatment must be weighed against long-term costs
(eg, monitoring requirements, adjunctive procedures).
The health care practitioner, cognizant of the state of art
for existing therapies, is the most competent to instruct
the patient with an accurate informed consent for making
the definitive decision.
The significant morbidity reduction and improved
quality of life accompanying this less-invasive procedure
can provide a treatment option for patients too ill to tol-
erate an open procedure. However, with operative mor-
tality currently reported as similar for endovascular and
open treatments of AAA, the risk of death, unlike periop-
erative morbidity, probably should not be a major consid-
eration in deciding on treatment options for the individual
patient.
The need exists at present, imposed by a risk of treat-
ment failure, for indefinite postimplantation surveillance
with imaging of endovascular grafts. This should enter into
any decision to expand the indications for AAA treatment
with this minimally invasive procedure. The intensity of
monitoring an AAA of borderline size with abdominal
ultrasound is far less onerous than that required at this time
after endovascular treatment. This should also be a factor
in decisions about endovascular treatment of younger
patients when driven primarily by concerns for possible loss
of sexual performance after an open procedure.
Endovascular procedures are foreign to the average
vascular surgeon’s experience and have a very definite
learning curve. The FDA requires sponsors of approved
endovascular grafts to conduct training programs to atten-
uate this learning curve. Credentialing committees of
institutions introducing endovascular procedures should
ensure that operators evaluated to perform this new pro-
cedure have participated in such training. 
Endovascular treatment for AAA unquestionably
offers a promising approach for addressing AAA occurring
with increasing frequency in an aging population with its
accompanying comorbidity. The physician with a clinical
background and training in the treatment of vascular dis-
ease, as the vascular surgeon is, must take the lead in the
further development of this therapeutic intervention and
direct the inevitable expansion to the treatment of other
manifestations of vascular disease.
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